Division of Gynecologic Oncology, McMaster University, Hamilton, Ontario, Canada.
Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
J Surg Oncol. 2022 Mar;125(3):437-447. doi: 10.1002/jso.26728. Epub 2021 Oct 22.
Despite quality evidence supporting postoperative extended venous thromboembolism prophylaxis (eVTEp) following abdominopelvic cancer surgery, baseline use of eVTEp at our institution was 3%. Our project aim was to improve the proportion of patients prescribed eVTEp following surgery for gynecologic, hepatobiliary, and colorectal cancers by a 30% absolute increase.
We performed an interrupted time series study using quality improvement methodology. Postoperative order sets, pre-printed prescriptions, process checklists, and multimodal education were introduced. Process and outcome data were collected and analyzed on statistical process control charts.
We included 324 patients with gynecologic and hepatobiliary cancers. Despite efforts to include them, the colorectal team did not participate. The monthly mean order set-use was 58% (SD = 14%), by specialty: gynecology 79%, hepatobiliary 47%. The proportion of patients prescribed eVTEp increased from 3% to 70% (SD = 14%). The target goal was surpassed and sustained by both cohorts. Patient compliance was 73% (n = 117/160, SD = 16%). Of those who stopped eVTEp early, 45% (n = 14/31) objected because of the injectable nature. Bleeding events were infrequent (0.6%, n = 2/324).
Three process changes and multimodal education resulted in a significant increase in eVTEp use. Failure to identify improvement champions limited project expansion to colorectal patients. Patient compliance was largely limited by the injectable nature of the medication.
尽管有高质量的证据支持腹部骨盆癌症手术后进行术后延伸性静脉血栓栓塞症预防(eVTEp),但我们机构基线时 eVTEp 的使用率仅为 3%。我们的项目目标是通过将接受妇科、肝胆和结直肠癌症手术的患者中接受 eVTEp 治疗的比例提高 30%。
我们采用质量改进方法进行了一项间断时间序列研究。引入了术后医嘱集、预印处方、流程检查表和多模式教育。收集并在统计过程控制图上分析流程和结果数据。
我们纳入了 324 例妇科和肝胆癌症患者。尽管努力将他们包括在内,但结直肠团队并未参与。每月医嘱集使用率的平均值为 58%(SD=14%),按专业划分:妇科为 79%,肝胆为 47%。接受 eVTEp 治疗的患者比例从 3%增加到 70%(SD=14%)。两个队列均超过并维持了目标。患者的依从率为 73%(n=117/160,SD=16%)。提前停止 eVTEp 的患者中有 45%(n=14/31)因药物为注射剂而提出反对。出血事件很少见(0.6%,n=324)。
三项流程变更和多模式教育导致 eVTEp 使用显著增加。未能确定改进的拥护者限制了项目在结直肠患者中的扩展。患者的依从性主要受到药物为注射剂的限制。